Autopsy report · NCT01659138
Efficacy and Safety of SAR339658 in Patients With Moderate to Severe Ulcerative Colitis
Cause of deathSlow enrollment, also safety
“Recruitment was early terminated due to slow recruitment. Not linked to any safety concern.”
Life of this trial
- Ran for about 3 years 8 months before it stopped.
- 28 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Sanofi
- Sponsor type
- Industry
- Conditions
- Ulcerative Colitis
- Interventions
- SAR339658; Placebo
- Participants
- 28
- Sites
- 41
- Countries
- Austria, Canada, France, Germany, Italy, Poland, United States
Trials that died the same way
- Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab
“The recruitment was terminated early due to delays and slow recruitment that significantly jeopardized the trial timelines. There were no safety concerns related to the early termination of the trial.” - Cromoglicate in Mastocytosis
“prematurely terminated because of low recruitment” - Paracetamol Versus Placebo in Conjunction With Strong Opioids for Cancer Pain
“Funding was terminated early due to slow recruitment.” - Phase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITP
“Terminated due to recruitment not meeting expectations.” - Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease
“terminated due to slow recruitment”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.